ING200336: A Prospective, Interventional Pharmacokinetic and Safety Study of DTG/ABC/3TC in Pregnant Women
Phase of Trial: Phase III
Latest Information Update: 02 Mar 2017
At a glance
- Drugs Abacavir/dolutegravir/lamivudine (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors GlaxoSmithKline; ViiV Healthcare
- 07 Jun 2017 Biomarkers information updated
- 24 Feb 2017 Planned primary completion date changed from 1 Feb 2019 to 1 Oct 2021.
- 05 Jul 2016 Planned End Date changed from 1 Feb 2019 to 1 Oct 2021.